12:00 AM
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Inavir laninamivir: Phase III started

Biota said that Daiichi Sankyo began a double-blind, placebo-controlled Phase III trial to evaluate 2 doses of Inavir laninamivir in 1,500 healthy family members of a...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >